Instruction for use: Dopegyt

Trade name of the drug – Dopegyt

ATX code C02AB02 methyldopa (racemic mixture)

Pharmacotherapeutic group: Stimulant of central alpha2-adrenergic receptors. Antihypertensives [alpha agonists] 

The nosological classification (ICD-10)

I10 Essential (primary) hypertension

Hypertension, Arterial hypertension, Arterial hypertension crisis course, Essential Hypertension

Primary hypertension, Arterial hypertension, complications of diabetes, hypertension, The sudden increase in blood pressure, Hypertensive disorders of blood circulation, hypertensive condition, hypertensive crises, hypertension, arterial Hypertension, malignant Hypertension, Hypertonic disease, Hypertensive crisis, Hypertension, accelerated hypertension, malignant hypertension, The aggravation of hypertensive disease, Transient hypertension, Isolated systolic hypertension

I15 Secondary hypertension

Arterial hypertension, complications of diabetes, hypertension, The sudden rise in blood pressure, Hypertensive disorders of blood circulation, hypertensive condition, hypertensive crises, hypertension, arterial hypertension, malignant hypertension, Hypertensive crisis, Hypertension, accelerated hypertension, malignant hypertension, hypertensive crisis, The aggravation of hypertensive disease, Transient hypertension, hypertension, Arterial hypertension, Arterial hypertension crisis course, renovascular hypertension, symptomatic hypertension, renal hypertension, Renovascular hypertension, Symptomatic hypertension

Composition

Tablets 1 tab.

active substance:

sesquihydrate methyldopa 282 mg

(Equivalent to 250 mg of methyldopa)

Excipients: ethyl cellulose - 8.8 mg; Magnesium stearate - 1 mg; corn starch - 45.7 mg; stearic acid - 3 mg; Sodium carboxymethyl - 3.5 mg; talc - 6 mg

Dosage and Administration

Inside. Drug therapy Dopegit® requires individual dose adjustment. The drug can be taken both before and after a meal.

Adult patients. The recommended initial dose of drug Dopegit® the first 2 days of therapy is 250 mg 2-3 times a day. Thereafter, the dosage may be gradually increased or decreased (depending on the degree of reduction of blood pressure). The duration of the intervals between the increase and decrease in the dose of the drug Dopegit® should be at least 2 days. As for 2-3 days after initiation of therapy, as well as the subsequent increase in dose can be observed sedative side effect of the drug, it is recommended to increase the evening dose.

The standard maintenance dose of the drug is Dopegit® 500-2000 mg / day. This dose is divided into 2-4 reception. The maximum daily dose should not exceed 3000 mg. In cases where the intake of the drug at a dose of 2000 mg / day is marked lack of effective reduction of blood pressure is recommended to combine Dopegit® with other antihypertensive agents.

After 2-3 months of therapy to methyldopa may develop tolerance. Effective reduction of blood pressure level can be achieved by increasing the dose of the drug or the concomitant use of diuretics.

After 48 hours after the cessation of drug therapy Dopegit® blood pressure usually returns to its original level. rebound effect is not observed.

Dopegit® The drug can be administered to patients who are already receiving therapy with other antihypertensive agents, subject to the gradual abolition of these drugs. In such cases, the initial dose of the drug Dopegit® should not exceed 500 mg / day. Increasing the dose is carried out as necessary, at intervals of not less than 2 days.

When applying Dopegit® drug in addition to the previously assigned antihypertensive therapy, in order to ensure a smooth transition may require adjustment of doses of antihypertensive drugs.

Elderly patients. Older patients drug is given in a minimum initial dose should not exceed 250 mg / day. If necessary, the dose can be gradually increased. The duration of intervals between dosage increase is not less than 2 days. The maximum daily dose Dopegit® drug should not exceed 2000 mg.

Older patients are more frequently observed fainting. It may be associated with increased susceptibility to the drug and severe atherosclerotic vascular disease. Development of syncope can be avoided by reducing the dose of the drug Dopegit®.

Children older than 3 years. For children, the initial dose is 10 mg / kg / day. The daily dose is divided into 2-4 reception. If necessary, the dose can be gradually increased until it reached the desired effect. Between increasing dose range should be observed for at least 2 days. Dopegit® maximum daily dose of the drug is 65 mg / kg / day, but not more than 3 g / day.

Impaired renal function. Methyldopa appears mainly by the kidneys, so in the treatment of patients with impaired renal function, a dose of the drug should be reduced Dopegit®. In mild renal insufficiency (glomerular filtration rate (GFR) 60-89 ml / min / 1.73 m2), the interval between doses of the drug should be increased to 8 hours, in patients with renal insufficiency of moderate severity - up to 8-12 hours (GFR 30-59 ml / min / 1.73 m 2), and in severe renal insufficiency - up to 12-24 hours (GFR <30 mL / min / 1.73 m2).

Methyldopa is removed from the body by dialysis, it is recommended to use the extra dose of 250 mg for the prevention of increase in blood pressure after hemodialysis session.

release Form

Tablets, 250 mg. According to Table 50. brown glass vial with PE-cap with the control of the first opening and shock-accordion. 1 fl. in a cardboard bundle.

Available without prescription

Storage conditions of Dopegyt

At a temperature of 15 to 25 ° C.

Keep out of the reach of children.
Shelf life of Dopegyt

5 years.

Do not use beyond the expiration date printed on the package.